Pancreatic endocrine tumors

Problems in General Surgery

Volumn 20, Issue 3, 2003, Pages 112-124

  Doherty, Gerard M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GASTRIN; GLUCAGON; GLUCOSE; GROWTH HORMONE RELEASING FACTOR; INSULIN; OCTREOTIDE; OMEPRAZOLE; PENTETREOTIDE; PNEUMOCOCCUS VACCINE; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACROMEGALY; ANAMNESIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CUSHING SYNDROME; DIFFERENTIAL DIAGNOSIS; GASTRINOMA; GLUCAGONOMA; GLUCOSE BLOOD LEVEL; HORMONAL REGULATION; HUMAN; INSULINOMA; LABORATORY DIAGNOSIS; MEDICAL DECISION MAKING; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS FUNCTION; PANCREAS ISLET CELL TUMOR; PANCREAS RESECTION; PATHOGENESIS; POSTOPERATIVE INFECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SOMATOSTATINOMA; SPLENECTOMY; STREPTOCOCCUS INFECTION; SURGICAL APPROACH; SURGICAL TECHNIQUE; TREATMENT PLANNING; VIPOMA; ZOLLINGER ELLISON SYNDROME;

EID: 0141508904     PISSN: 07398328     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013452-200309000-00013     Document Type: Review

References (47)

1. Lange JR, Steinberg SM, Doherty GM, et al. A randomized, prospective trial of postoperative somatostatin analogue in patients with neuroendocrine tumors of the pancreas. Surgery 1992;112:1033-1037, discussion 1037-1038.
2. Dizon A, Kowalyk S, Hoogwerf B. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med 1999;106:307-310.
3. Doherty GM, Doppman JL, Shawker TH, et al. Results of a prospective strategy to diagnose, localize, and resect insulinomas. Surgery 1991;110:989-996, discussion 996-997.
4. Hirshberg B, Livi A, Bartlett DL, et al. Forty -eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab 2000;85:3222-3226.
5. Falconi M, Molinari E, Carbognin G, et al. What preoperative assessment is necessary for insulinomas? Calculating the degree of waste: analysis of 29 cases. Chir Ital 2002;54:597-604.
6. Nesje LB, Varhaug JE, Husebye ES, et al. Endoscopic ultrasonography for preoperative diagnosis and localization of insulinomas. Scand J Gastroenterol 2002;37: 732-737.
7. Ardengh J, Rosenbaum P, Ganc A, et al. Role of EUS in the preoperative localization of insulinomas compared with spiral CT. Gastrointest Endosc 2000;51:552-555.
8. Hashimoto L, Walsh R. Preoperative localization of insulinomas is not necessary. J Am Coll Surg 1999;189: 368-373.
9. Cohen MS, Picus D, Lairmore TC, et al. Prospective study of provocative angiograms to localize functional islet cell tumors of the pancreas. Surgery 1997;122: 1091-1100.
10. Hiramoto JS, Feldstein VA, LaBerge JM, et al. Intraoperative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg 2001;136: 1020-1025, discussion 1020-1025.
11. van Heerden JA, Grant CS, Czako PF, et al. Occult functioning insulinomas: which localizing studies are indicated? Surgety 1992;112:1010-1015.
12. Grant CS, van Heerden J, Charboneau JW, et al. Insulinoma: the value of intraoperative ultrasonography. Arch Surg 1988;123:843-848.
13. Minni F, Marrano N, Pasquali R. Laparoscopic body-tail pancreatic resection for insulinoma. Surg Endosc 2003;17:159-160.
14. Takamatsu S, Teramoto K, Inoue H, et al. Laparoscopic enucleation of an insulinoma of the pancreas tail. Surg Endosc 2002;16.
15. Tagaya N, Ishikawa K, Kubota K. Spleen-preserving laparoscopic distal pancreatectomy with conservation of the splenic artery and vein for a large insulinoma. Surg Endosc 2002;16:217-218.
16. Mahon D, Allen E, Rhodes M. Laparoscopic distal pancreatectomy. Three cases of insulinoma. Surg Endosc 2002;16:700-702.
17. Gramatica L Jr, Herrera MF, Mercado-Luna A, et al. Videolaparoscopic resection of insulinomas: experience in two institutions. World J Surg 2002;26:1297-1300.
18. Fernandez-Cruz L, Saenz A, Astudillo E, et al. Outcome of laparoscopic pancreatic surgery: endocrine and non-endocrine tumors. World J Surg 2002;26:1057-1065.
19. Iihara M, Kanbe M, Okamoto T, et al. Laparoscopic ultrasonography for resection of insulinomas. Surgery 2001;130:1086-1091.
20. Cogliandolo A, Pidoto RR, Causse X, et al. Minimally invasive management of insulinomas. A case report. Surg Endosc 2001;15.
21. Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis-a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine 2001;80:189-222.
22. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine 2000;79:379-411.
23. Gibril F, Venzon DJ, Ojeaburu JV, et al. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a non-aggressive form. J Clin Endocrinol Metabol 2001; 86:5282-5293.
24. Albertario S, Forti P, Bianchi C, et al. Radioguided surgery for gastrinoma: a case report. Tumori 2002;88: S41-S43.
25. Gibril F, Reynolds J, Chen C, et al. Specificity of somatostatin receptor in scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999;40:539-553.
26. Meko JB, Doherty GM, Siegel BA, et al. Evaluation of somatostatin-receptor scintigraphy for detecting neuroendocrine tumors. Surgery 1996;120:975-983, discussion 983-984.
27. 111Inpentetreotide scanning versus conventional imaging techniques for the localization of gastrinoma. Surgery 1995;0:0.
28. Thompson NW, Czako PF, Fritts LL. Role of endoscopic ultrasonography in the localization of insulinomas and gastrinomas. Surgery 1994;116:1131-1138.
29. Mitchell DG, Cruvella M, Eschelman DJ, et al. MRI of pancreatic gastrinomas. J Comput Assist Tomogr 1992; 16:583-585.
30. Thompson NW, Pasieka J, Fukuuchi A. Duodenal gastrinomas, duodenotomy, and duodenal exploration in the surgical management of Zollinger-Ellison syndrome. World J Surg 1993;17:455-462.
31. Sugg SL, Norton JA, Fraker DL, et al. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg 1993;218: 138-144.
32. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999;341:635-644.
33. Norton JA, Doherty GM, Fraker DL, et al. Surgical treatment of localized gastrinoma within the liver: a prospective study. Surgery 1998;124:1145-1152.
34. Stabile BE, Morrow DJ, Passaro E. The gastrinoma triangle: operative implications. Am J Surg 1984; 147: 25-31.
35. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome: results of a 10 year prospective study. Ann Surg 1992;215:8-18.
36. O'Dorisio TM, Mehkjian HS, Gaginella TS. Medical therapy of VIPomas. Endocrinol Metab Clin North Am 1989;18:545-550.
37. Mekhjian HS, O'Dorisio TM, VIPoma syndrome. Semin Oncol 1987;14:282.
38. O'Dorisio TM, Mekhjian HS. VIPoma syndrome. In: Cohen S, Soloway RD, eds. Hormone Producing Tumors of the Pancreas New York, NY: Churchill Livingstone; 1985:101-0.
39. Boden G, Ryan IG, Eisenschmid D, et al. Treatment of inoperable glucagonoma with the long-acting somatostatin analog SMS-201-995. N Engl J Med 1986;314: 1686-1689.
40. Boden G. Glucagonomas and insulinomas. Gastroenterol Clin North Am 1989;18:831.
41. Skogseid B, Doherty GM. Multiple endocrine neoplasia type 1: clinical and genetic features. Dig Liver Dis 1999;31:S131-S134.
42. Skogseid B, Grama D, Rastad J, et al. Operative tumour yields obviates preoperative pancreatic tumor localization in multiple endocrine neoplasia type 1. J Intern Med 1995;238:281-288.
43. Skogseid BS, Rastad J, Oberg K. Multiple endocrine neoplasia type 1: clinical features and screening. Endocrinol Metab Clin North Am 1994;23:1-18.
44. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
45. Lairmore TC, Chen VY, DeBenedetti MK, et al. Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2000;231: 909-918.
46. Doherty GM, Olson JA, Frisella MM, et al. Lethality of multiple endocrine neoplasia type 1. World J Surg 1998; 22:581-586, discussion 586-587.
47. Norton JA, Alexander HR, Fraker DL, et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001;234: 495-505, discussion 505-506.